CN1158133A - 肽衍生的放射性核素螯合剂 - Google Patents
肽衍生的放射性核素螯合剂 Download PDFInfo
- Publication number
- CN1158133A CN1158133A CN95195127A CN95195127A CN1158133A CN 1158133 A CN1158133 A CN 1158133A CN 95195127 A CN95195127 A CN 95195127A CN 95195127 A CN95195127 A CN 95195127A CN 1158133 A CN1158133 A CN 1158133A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- amino
- carboxyl
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 50
- 239000002738 chelating agent Substances 0.000 title abstract description 16
- -1 amino, carboxyl Chemical group 0.000 claims abstract description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 27
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 24
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 17
- 150000002367 halogens Chemical class 0.000 claims abstract description 17
- 125000003118 aryl group Chemical group 0.000 claims abstract description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 11
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 11
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 41
- 229910052751 metal Inorganic materials 0.000 claims description 27
- 239000002184 metal Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 125000000217 alkyl group Chemical class 0.000 claims description 16
- 238000002601 radiography Methods 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 150000004767 nitrides Chemical class 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 230000008685 targeting Effects 0.000 abstract description 10
- 125000001424 substituent group Chemical group 0.000 abstract description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 150000008575 L-amino acids Chemical class 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 239000003352 sequestering agent Substances 0.000 description 42
- 239000000562 conjugate Substances 0.000 description 25
- 230000008878 coupling Effects 0.000 description 17
- 238000010168 coupling process Methods 0.000 description 17
- 238000005859 coupling reaction Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229910052713 technetium Inorganic materials 0.000 description 7
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 150000003053 piperidines Chemical class 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- QDWVRVNMKUFQJL-UHFFFAOYSA-N 2-(dibenzylamino)acetic acid Chemical compound C=1C=CC=CC=1CN(CC(=O)O)CC1=CC=CC=C1 QDWVRVNMKUFQJL-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229910052702 rhenium Inorganic materials 0.000 description 3
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- SGXDXUYKISDCAZ-UHFFFAOYSA-N N,N-diethylglycine Chemical compound CCN(CC)CC(O)=O SGXDXUYKISDCAZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- FFOKMZOAVHEWET-IMJSIDKUSA-N Ser-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H](CS)C(O)=O FFOKMZOAVHEWET-IMJSIDKUSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MWOGMBZGFFZBMK-LJZWMIMPSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWOGMBZGFFZBMK-LJZWMIMPSA-N 0.000 description 1
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- RLCSROTYKMPBDL-USJZOSNVSA-N 2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-methylbutanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RLCSROTYKMPBDL-USJZOSNVSA-N 0.000 description 1
- RDOAUPPSCNSYPM-UHFFFAOYSA-N 3,4-dihydropyridine Chemical compound C1CC=NC=C1 RDOAUPPSCNSYPM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 244000086443 Craterellus fallax Species 0.000 description 1
- 235000007926 Craterellus fallax Nutrition 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical group CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical class CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical group OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229910002785 ReO3 Inorganic materials 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000008155 medical solution Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 108010083018 monocyte locomotion inhibitory factor Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000003608 radiolysis reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- YSZJKUDBYALHQE-UHFFFAOYSA-N rhenium trioxide Chemical compound O=[Re](=O)=O YSZJKUDBYALHQE-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- MSXHSNHNTORCAW-GGLLEASOSA-M sodium;(2s,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].O[C@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O MSXHSNHNTORCAW-GGLLEASOSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 108010001535 sulfhydryl oxidase Proteins 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 108010052768 tyrosyl-isoleucyl-glycyl-seryl-arginine Proteins 0.000 description 1
- 108010011876 valyl-glycyl-valyl-alanyl-prolyl-glycine Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供了式(I)放射性核素螯合剂,以用在体内要诊断的显影位点。式(I)中X是直链或支链的、饱和或不饱和C1-4烷基链,此烷基链可任选地插入一个或两个选自N、O和S的杂原子;并且可任选地被至少一个选自卤素、羟基、氨基、羧基、C1-4烷基、芳基和C(O)Z的基团取代;Y是H或X限定的取代基;X和Y可以一起形成一个5-至8-元的饱和或不饱和杂环,该杂环可任选地被至少一个选自卤素、羟基、氨基、羧基、氧化、C1-4烷基、芳基和C(O)Z的基团取代;R1至R4各自独立地选自H、羧基;C1-4烷基;被选自羟基、氨基、巯基、卤素、羧基、C1-4烷氧羰基和氨基羰基的基团取代的C1-4烷基;除脯氨酸的D-或L-氨基酸的α-碳侧链;C(O)Z;R5和R6各自独立地选自H;羧基;氨基;C1-4烷基;被羟基、羧基或氨基取代的C1-4烷基;和C(O)Z;R7选自H和硫保护基;Z选自羟基、C1-4烷氧基和靶向性分子。
Description
发明领域
本发明属于诊断造影领域,涉及用来对以所要诊断的组织为靶的试剂进行放射性标记的化学螯合剂。
发明背景
诊断造影技术中采用造影剂,其选择性地结合或定位于体内位点,帮助分辨所要诊断部位的影象。例如67镓盐具有对肿瘤和被感染组织的亲和性,并且借助于X射线断层扫描照相术能够使医生发现受伤的体内组织。其它造影剂包括金属放射性核素,如99m锝和186/188铼,其已被用来标记靶向分子,诸如位于人体特定部位的蛋白质、肽和抗体。
作为靶向试剂,蛋白质和其它大分子能提供满足诊断准确性要求的组织特异性;但从其物质结构而言,用金属放射性核素标记这些试剂很困难。具体而言,蛋白质和肽靶向试剂存在可与放射性核素结合的多个位点,从而得到不均匀标记的产物。而且,尽管这些蛋白质分子可能很大,但其很少能呈现出一种最适于与高亲和性放射性核素结合的结构构型,即结合有4个或多个供体原子形成5元环的区域,因此,放射性核素通常被结合于较为丰富的低亲和性位点,形成不稳定配合物。
为解决这种低亲和力结合问题,Paik等人(Nucl Med Biol 1985,12:3)提出了一种方法,其中在过量DPTA(二氨亚丙基五乙酸)存在下对抗体进行标记,使低亲和力结合位点隐蔽起来。虽然通过这种方法能避免低亲和力结合问题,但这种情况中实际上放射性核素锝的结合量最终仍是很低的。已有文献报道了具有高半胱氨酸残基比例的蛋白质的直接标记(Dean等;WO 92/13572)。该方法利用了半胱氨酸残基中的巯基作为放射性核素结合的高亲和性位点,并且该方法必须限于应用在那些具有所需巯基结构的靶向性试剂中。
代替靶向性试剂直接标记的一种可行方法是采用间接标记途径,其中使用一螯合剂使靶向性试剂和放射性核素偶联。用作螯合剂的候选物是那些与所选金属放射性核素紧密结合的并且还具有与靶向性分子结合的反应官能团的化合物。为用于标记肽和以蛋白质为基础的靶向性试剂,理想的螯合剂也是以肽为基础的,如此可使用肽合成技术全部合成这些螯合剂-靶向性分子共轭物,为用于诊断造影,理想的螯合剂应具有适于体内应用的性质,诸如血和肾清除性及血管外扩散性。
发明概述
本发明提供了与诊断用金属放射性核素键连的螯合剂,其能与可在体内定位欲诊断位点和欲治疗位点的靶向性试剂偶联。本发明螯合剂为肽类似物,设计其结构存在N3S构型,能键连氧代、二氧代和99m锝及186/188铼的次氮基离子。
其中
X是一直链或支链的、饱和或不饱和的C1-4烷基链,该烷基链可任选地插入一个或两个选自N、O和S的杂原子;并且可任选地被至少一个选自卤素、羟基、氨基、羧基、C1-4烷基、芳基和C(O)Z的基团取代;
Y是H或由X定义的取代基;
X和Y一起形成一个5-至8-元饱和或不饱和杂环,该杂环可任选地被至少一个选自卤素、羟基、氨基、羧基、氧代、C1-4烷基、芳基和C(O)Z的基团取代;
R1至R4各自独立地选自H;羧基;C1-4烷基;被选自羟基、氨基、巯基、卤素、羧基、C1-4烷氧羰基和氨基羰基的一个基团取代的C1-4烷基;除脯氨酸外的D-或L-氨基酸的α-碳侧链;和C(O)Z;
R5和R6各自独立地选自H;羧基;氨基;C1-4烷基;被羟基、羧基或氨基取代的C1-4烷基;和C(O)Z;
R7选自H和硫保护基;及
Z选自羟基、C1-4烷氧基和靶向性分子。
其中
X是一直链或支链、饱和或不饱和C1-4烷基链,该烷基链可任选地插入一个或两个选自N、O和S的杂原子;并且可任选地被至少一个选自卤素、羟基、氨基、羧基、C1-4烷基、芳基和C(O)Z的基团取代;
Y是H或X定义的取代基;
X和Y一起形成5-至8-元饱和或不饱和杂环,该杂环可任选地被至少一个选自卤素、羟基、氨基、羧基、氧代、C1-4烷基、芳基和C(O)Z的基团取代;
R1至R4各自独立地选自H;羧基;C1-4烷基;被一个选自羟基、氨基、巯基、卤素、羧基、C1-4烷氧羰基和氨基羰基的基团取代的C1-4烷基;除脯氨酸外的D-或L-氨基酸的α碳侧链;和C(O)Z;
R5和R6各自独立地选自H;羧基;氨基;C1-4烷基;被羟基、羧基或氨基取代的C1-4烷基;和C(O)Z;
Z选自羟基、C1-4烷氧基和一个靶向性分子;
M是一金属放射性核素或其氧化物或氮化物。
本发明另一方面提供了一种用于造影的共轭物,其中螯合剂所呈形式是与诊断用靶向性分子偶联,并可任选地与配合的金属放射性核素结合。
本发明另一方面提供了一种在所要诊断位点进行造影的方法,其中首先对病人施用作为放射性核素配合物的本发明共轭物,然后用造影方法探测放射性核素所处部位。
附图简述
图1为以99mTc标记的N,N-二甲基Gly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg-OH共轭物的HPLC分析结果。
发明详述
本发明提供了金属放射性核素螯合剂,当其与靶向性分子偶联时,能用来将放射性核素递送至所要治疗或诊断的身体部位。正如上式中所示,该螯合剂为肽化合物,其呈现N3S构型,其中放射性核素被螯合。
这里所用的定义R1-R7、X、Y和Z各种变化的术语含义如下:
“烷基”指直链或支链C1-4链;
“芳基”指芳香环或杂芳香环;
“卤素”指F、Cl和Br;
“硫保护基”指抑制巯基氧化的化学基团,包括那些在金属螯合作用时可被裂解的基团。适合的硫保护基包括已知的烷基、芳基、酰基、链烷酰基、芳酰基、巯酰基和有机硫代基。
在本发明优选实施方案中,螯合剂符合上式,其中
R1至R4各自独立地选自H;羟基取代的C1-4烷基,如羟甲基和1-羟乙基;
R5和R6各自独立地选自H和C1-4烷基,优选均为H;
R7是氢原子或硫保护基,且最优选乙酰氨基甲基;
X是C1-4烷基链,优选甲基或乙基;或被芳基取代的C1-4烷基链,优选形成苄基;
Y是H或X定义的取代基;优选甲基、乙基或苄基,最优选为与X相同;
Z是OH,C1-4烷氧基或一靶向性分子,优选肽靶向性分子。
本发明具体螯合剂包括:
N,N-二甲基Gly-Ser-Cys(Acm)-OH;
N,N-二甲基Gly-Thr-Cys(Acm)-OH;
N,N-二乙基Gly-Ser-Cys(Acm)-OH;
N,N-二苄基Gly-Ser-Cys(Acm)-OH;和
肌氨酸-Ser-Cys(Acm)-OH。
当X和Y代表的取代基与邻接的N原子形成一个杂环时,该环可以是5-至8-元饱和环,例如吡咯烷、哌啶、 1-氮杂环庚烷和1-氮杂环辛烷。由X和Y形成的不饱和环包括吡咯和4H-吡啶,显然环中结合的氮原子必须是三价的且不能与邻位原子形成双键。由X和Y形成的杂环也可包含另外一个或两个选自N、O和S的杂原子。具有另外杂原子的环包括1-咪唑、吡唑、哌嗪、吗啉和硫代吗啉,但不限于这些。由X和Y形成的环也可被一个或多个并优选少于三个基团取代,取代基选自卤素、羟基、羧基、氧代、C1-4烷基和芳基,例如形成4-氧代-1-哌啶、4-氧代-1-吡咯烷和4-羟基-1-哌啶。
为诊断造影目的,本质上螯合剂可呈与金属放射性核素成配合物形式。适宜的放射性核素包括99mTc、64Cu、67Cu、97Ru、105Rh、109Pd、186Re、188Re、198Au、199Au、203Pb、212Pb和212Bi的各种氧化物或氮化物。优选的金属放射性核素为氧化物形式的锝(99mTc)和铼(186,188Re),如ReO3+、ReO2 +、99mTcO2 +,最优选99mTcO3+。根据本发明优选方面,螯合剂与由上式中Z代表的靶向性分子偶联,形成一种结合物,用来向哺乳动物体中目标位点递送螯合的放射性核素。适于与螯合剂偶联的靶向性分子的例子包括但不限于甾族化合物、蛋白质、肽、抗体、核苷酸和糖类。优选靶向性分子包括蛋白质和肽,特别是那些能与具体病理特点的细胞表面受体进行特异结合的肽和蛋白。例如,通过标记与本发明螯合剂偶联的蛋白或其受体结合片段,可对特殊蛋白受体的超表达相关疾病进行造影。最优选的靶向性分子是肽,其能特异地结合于靶位点,且具有三个或多个氨基酸残基。用于某些疾病状况和组织造影的靶向性肽如下所示:针对动脉粥样硬化斑:
YRALVDTLK RALVDTLK
RALVDTLKFVTQAEGAK YAKFRETLEDTRDRMY
AKFRETLEDTRDRMY AALDLNAVANKIADFEL
YAALDLNAVANKIADFEL YRALVDTLKFVTEQAKGA
RALVDTLKFVTEQAKGA YRALVDTEFKVKQEAGAK
RALVDTEFKVKQEAGAK YRALVDTLKFVTQAEGAK针对感染和动脉粥样硬化斑:
VGVAPGVGVAPGVGVAPG 甲酰Nleu.LF.Nleu.YK
VPGVGVPGVGVPGVGVPGVG 甲酰MIFL
甲酰MLFK 甲酰MLFI
甲酰MFIL 甲酰MFLI
甲酰MLIF 甲酰MILF
甲酰TKPR VGVAPG
甲酰MLF YIGSR
CH2CO.YIGSRC针对血栓:
NDGDFEEIPEEYLQ NDGDFEEIPEEY(SO3Na)LQ
GPRG针对血小板:
D-Phe.PRPGGGGNGDFEEIPEEYL RRRRRRRRRGDV
PLYKKIIKKLLES RGD
RGDS针对淀粉样蛋白斑(早老性痴呆):
EKPLQNFTLSFR
为与螯合剂连接,靶向性分子可以包含一个“间隔臂”,以在螯合剂和靶向性分子间形成一个物理间隔。间隔臂可以是一烷基链,其被衍化用于与螯合剂偶联。当靶向性分子是肽时,间隔臂可以是适合的一个或多个氨基酸残基。优选肽靶向性分子含有1至5个氨基酸的间隔臂,这些氨基酸具有化学惰性的α-碳侧链,诸如甘氨酸或β丙氨酸残基。
靶向性分子可以在各种位点包括R1至R6、X、Y和Z及由X和Y形成的环与本发明螯合剂偶联。通过将靶向性分子上反应活性基团与螯合剂上的取代基反应,形成一连接键,完成偶联。例如,具有自由氨基象N-末端或有ε-氨基的Lys基团的肽靶向性分子可以与螯合剂的羧基反应,形成酰胺连接键。或者,肽靶向性分子的C-末端可以与螯合剂的氨基取代基反应。在优选实施方案中,靶向性分子通过一酰胺键如肽键在取代基Z处与式(I)螯合剂偶联。例如,肽靶向性分子的N-末端氨基与Z处的羧基反应。除肽外的靶向性分子,只要其具有适于与螯合剂偶联的基团,均可以以相似的方式与本发明螯合剂偶联。当适宜的基团不存在时,可以将靶向性分子化学衍生出这种基团。当螯合剂或靶向性分子上存在多于1个的反应基团时,应该用合适的封闭剂将除特定的偶联基团外的所有基团封闭,以获得单一共轭物。例如通过形成酯可将自由羧基保护起来,象叔丁酯,其可用TFA去除。用如FMOC封闭基可将自由氨基保护起来,用哌啶可随后将其去除。
在本发明一具体实施方案中,使用一共轭物对体内炎症病灶位点进行造影,其中靶向性分子是包含氨基酸序列Thr-Lys-Pro-Pro-Lys(TKPPR)的趋化性肽。已发现该肽能与白细胞受体很好地结合。通过附加的氨基酸残基(优选甘氨酸)可将靶向性肽与螯合剂间隔开,条件是肽仍保持其定位活性。在一具体实施方案中,通过一Gly残基将肽TKPPR与式(I)螯合剂的取代基Z偶联。
使用各种现有技术可制备以肽为基础的靶向性分子本身或将其与螯合剂一起制备成共轭物。由于其适于固相肽合成,所以采用交替的FMOC保护和去保护是制备短肽的优选方法。生产蛋白质或其长片段时优选用重组DNA技术。在一具体实施方案中,通过固相肽合成方法制备肽-螯合剂共轭物,包括向连接在不溶性(固体)支持物或基质如聚苯乙烯的增长的肽链上逐步增加氨基酸残基。首先将靶向性肽的C-末端残基键连到市售的支持物上,其氨基由N-保护剂如芴甲氧羰基(FMOC)保护。通常,支持物被预先连接上呈被保护形式的C-末端残基。用适宜的去保护试剂如哌啶除去氨基保护基,并用偶联剂如双环碳二亚胺(DCC)连接下一个氨基酸残基(呈N-被保护形式)。肽键形成时,从支持物上洗去反应试剂。一旦合成靶向性肽链,则要向N末端加上螯合剂的第一个残基即S-乙酰氨基甲基保护的半胱氨酸。螯合剂的最后残基是衍生的氨基酸残基,其形成了式(X)(Y)N-C(R1)(R2)-CO-,其中X、Y、R1和R2的定义如前所述。最后一个残基,例如二甲基甘氨酸、二乙基甘氨酸、二苄基甘氨酸或肌氨酸,均可市购或合成。用适宜的试剂如三氟乙酸(TFA)从载体上解离下该完整的共轭物。
显然,根据本发明,所有取代基R1至R4均为天然存在或衍生的氨基酸,包括D-氨基酸的侧链,其可市购且适于固相合成技术。对于购买不到的衍生氨基酸残基,根据现有有机化学技术合成这些氨基酸并在上述固相肽合成的适宜期间插入这些氨基酸,从而可使其掺人本发明螯合剂中。与此类似,当取代基R5和R6不是H时,在肽合成中使用衍生半胱氨酸残基。例如,当R5和R6均为甲基时,掺入市售的青霉胺残基。
通过将X和Y的各种取代基作为固相合成中的最后残基,如式(X)(Y)N-C(R1)(R2)-C(O)-OH所示的衍生的氨基酸,可将其掺入本发明螯合剂中,其中X、Y、R1和R2的含义同前。根据现有有机化学方法和技术可以合成具有N-末端氨基取代基X和Y的氨基酸。例如,当X和Y均为二苄基取代基时,可通过在适当的溶剂如二氯甲烷中将市售试剂溴乙酸和二苄胺反应,然后加热,合成出相应的二苄基甘氨酸残基。在反应中可采用其它胺代替二苄胺,如二异丙胺,得到相应的二异丙基甘氨酸。与此类似,用哌啶和吗啉这种环胺代替二苄胺,可得到相应的哌啶基甘氨酸和吗啉基甘氨酸残基。
在本发明最优选的实施方案中,在固相载体上制备肽-螯合剂共轭物,其具有式(I)结构,其中靶向性分子是序列为Gly-Thr-Lys-Pro-Pro-Arg-OH的肽;R1、R2、R3、R5和R6是H;R4是羟甲基或1-羟乙基,R7是乙酰氨基甲基。
通过各种已知方法可在螯合剂中掺入所选择的放射性核素。例如可使用下述常规方法。首先将螯合剂溶解于乙醇水溶液如乙醇-水1∶1中形成螯合剂溶液。用例如N2排气,除去O2,然后加入氢氧化钠除去巯基保护基,将溶液再次除净氧气,并水浴加热使巯基保护基水解,然后用有机酸如乙酸将溶液中和(pH6.0-6.5)。在标记步骤中,向螯合剂溶液中加入高锝酸钠和足以还原锝的氯化亚锡。将溶液混合,置于室温下反应然后水浴加热。在另一种方法中,可用调至pH8的螯合剂溶液进行标记。在这种较高pH值时,可用含锝的溶液代替高锝酸盐,锝配合有不稳定配基,适于与所需螯合剂进行配基交换反应。适宜的配基包括酒石酸盐、柠檬酸盐和七葡糖酸盐。若螯合溶液另被调节至更高pH如pH12-13,用于标记步骤,则可用连二亚硫酸钠作为还原剂代替氯化亚锡。本发明螯合剂在用放射性核素标记之前可与靶向性分子偶联,此方法即指“双功能螯合”法。另一种途径是“预先标记配基”法,其中先以放射性核素标记螯合剂,再将螯合剂与靶向性分子偶联。
可通过色谱法,例如使用先以乙醇活化然后再用稀HCl活化的C-18Sep Pak柱,可将被标记的螯合剂从污染物99mTcO4和胶态99mTcO2中分离出来。用稀盐酸洗脱分离出99mTcO4,用乙醇-盐水1∶1洗脱带出螯合剂,而胶态99mTcO2存留在柱中。
当本发明螯合剂与靶向性分子偶联并用诊断用金属标记时,可通过诊断造影领域常规技术将其用于检测病理状况。可对哺乳动物施用以放射性核素金属如锝标记的螯合剂-靶向性分子结合物,淋巴内、腹膜内且优选静脉内给予药用溶液中如生理盐水或血浆介质中的药。被标记结合物的给药量取决于所选靶向性分子的毒性曲线和金属的毒性曲线,通常每70kg病人给药范围在0.01至100且优选10至50mCi。通过标准闪烁照相技术在给药后适当的时间体内追踪金属的位置。可获得影象的时间取决于靶向性分子的分布曲线,例如大多数肽会很快定位,使得在3小时之内便可获得影象,通常在1小时之内即可。在一具体实施方案中,通过静脉注射.施用本发明偶联于肽靶向性分子GTKPPR的螯合剂的盐水溶液,对病灶炎症部位进行造影。
下述实施例用于说明本发明的一些实施方案。实施例1-制备肽-螯合剂共轭物
N,N-二甲基Gly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg
N,N-二甲基Gly-Thr-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg和
肌氨酸-Gly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg
使用FMOC化学法通过固相肽合成技术制备标题共轭物单链肽,使用应用生物系统433A肽合成仪(Foster City,CA)在预先接有FMOC-精氨酸的2-甲氧基-4-烷氧基苯甲醇树脂(Sasrin Resin,Bachem生命科学公司,费城)上进行合成。在链延伸的适当步骤中掺入衍生的氨基酸残基S-乙酰氨基甲基半胱氨酸(Bachem)、N,N-二甲基甘氨酸(Sigma化学公司,St.Louis.MO)和肌氨酸。
在加入最后一个残基N,N-二甲基甘氨酸或肌氨酸后,将肽树脂在真空条件下过夜干燥,并在室温下将9.5mL三氟乙酸(TFA),0.5ml水、0.5ml茴香硫醚和0.25ml 2-乙二硫醇的冷却溶液(每100mg肽树脂1ml)与肽树脂混合1.5至2小时,使肽从树脂上解离。过滤除去树脂,并用1-3mL TFA洗涤,得到6-8mL澄清的黄色液体。将此液体缓慢地滴入50ml锥形聚丙烯离心管中的30-35ml冷叔丁醚中,生成白色沉淀。0℃以7000rpm将该沉淀离心5分钟(Sorvall RT6000,Dupont),倾倒出上清液,用叔丁醚再洗涤两次。真空下干燥后,将该沉淀溶解于水中。在丙酮-干冰中冷冻溶液并将其冷冻干燥过夜。将所得白色粉末溶解于水,通过0.45μm注射过滤器(Gelman Acrodisc3CR PTFE)过滤,用C18柱(Waters RCM 25×10)反相HPLC(Beckman System Gold)进行纯化,以1%TFA水溶液为缓冲液A,1%TFA乙腈溶液为缓冲液B。用100∶0的缓冲液A:缓冲液B平衡柱子,以1mL/min在25分钟内线性梯度洗脱柱子至50%缓冲液B。级分在HPLC上进行再分析,并按匹配曲线收集级分。在丙酮-干冰中冷冻纯级分,并冷冻干燥12小时,得到白色粉末。实施例2-制备肽-螯合剂共轭物
N,N-二苄基Gly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg
N,N-二乙基Gly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg
使用FMOC化学法通过固相肽合成技术制备标题共轭物单链肽,使用应用生物系统433A肽合成仪(Foster City,CA)在预先载有FMOC-精氨酸的2-甲氧基-4-烷氧基苯甲醇树脂(Sasrin Resin,Bachem生命科学公司,费城)上进行合成。在链延伸的适当步骤中掺人衍生的氨基酸残基:S-乙酰氨基甲基-半胱氨酸(Bachem)、N,N-二乙基甘氨酸和N,N-二苄基甘氨酸。
用下述方法合成衍生的氨基酸残基N,N-二苄基甘氨酸:
在装有磁力搅拌子的烧瓶中,将溴乙酸(5.00g,35.99mmol)溶解于CH2Cl2,冷却至0℃,并加入二苄胺(8.31ml,43.79mmol)。反应混合物在O℃搅拌1小时,并温热至室温,然后在30-40℃之间加热12小时。将混合物溶液冷却至室温,减压条件下蒸发掉CH2Cl2,然后用热乙醇洗涤,并真空干燥得到白色固体残余物(71.2%产率)。
用下面的方法合成衍生的氨基酸残基N,N-二乙基甘氨酸:
在烧瓶中,向二乙胺(35mL)中加入氯乙酸(5.00g,52.91mmol),室温搅拌12小时,然后加热回流72小时。将反应混合物冷却至室温,并以HCl中和,浓缩使体积减小。然后力入乙酸乙酯和乙醇,过滤所得的白色沉淀并真空干燥,得到1.74g(25%产率)产物。
实施例3-标记肽-螯合剂共轭物
N,N-二甲基Gly-Ser-Cys(Acm)-GTKPPR
N,N-二甲基Gly-Thr-Cys(Acm)-GTKPPR
N,N-二乙基Gly-Ser-Cys(Acm)-GTKPPR
N,N-二苄基Gly-Ser-Cys(Acm)-GTKPPR和
肌氨酸Ser-Cys(Acm)-GTKPPR
重新制备实施例1和2的共轭物(200μl,1mg/ml盐水),然后将其与100μl高锝酸盐(10mCi)和100μl葡糖酸亚锡(50μg氧化亚锡和1mg葡糖酸钠)一起注射入3ml的真空容器。将此试管置于沸水浴中12分钟,然后通过Whatman PVDF注射过滤器过滤,收集被标记的共轭物溶液,进一步用盐水将其稀释,制得可注射用溶液(2Mbq/ml),通过HPLC(Beckman)从(20μl)样品中(在稀释前)分离该共轭物,通过测量放射活性确定标记率(labeling yield)。
共轭物 标记率
N,N-二甲基Gly-Ser-Cys(Acm)-GTKPPR >94%
N,N-二甲基Gly-Thr-Cys(Acm)-GTKPPR >94%
N,N-二乙基Gly-Ser-Cys(Acm)-GTKPPR 85.4%
N,N-二苄基Gly-Ser-Cys(Acm)-GTKPPR 98.9%
肌氨酸Ser-Cys(Acm)-GTKPPR 90.3%
除肌氨酸-Ser-Cys(Acm)-GTKPPR外每种结合物均出现单一峰,且标记率高于85%。标记24小时后,再在HPLC上重新分析N,N-二甲基Gly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg,没有发现降解或辐解产物。实施例4-共轭物的体内造影和生物分布
按下述方法进行大鼠炎症研究。在造影前24小时,用酵母聚糖(25mg),一种酵母细胞壁悬液,对2只雄性Wistar大鼠(CharlesRiver,200-250g)肌内注射入其左后腿。1天后可肉眼观察到腿部的炎症病灶。将1mg.(约0.7μmol)螯合剂-肽共轭物溶解于50μl二甲亚砜中,并加入到乙醇-水混合物(1∶1,200μl)中。加入Tc-99m酒石酸盐(约400MBq)等份溶液,100℃时进行转螯合作用(transchelation)20分钟。通过Sep Pak柱洗脱纯化Tc-99m标记的共轭物,然后用盐水稀释制得含约100μCi(3.7MBq)活性的可注射用制剂(200μl)。
用茄醇(40至50mg/kg)麻醉大鼠,然后通过尾静脉注射被标记的共轭物溶液(200μl)。需要连续全身闪烁扫描30分钟。然后超剂量麻醉杀死大鼠,称量器官、尿、血、已发炎的肌肉(左腿)和未发炎的肌肉(右腿)和炎症渗出物(液体)样品,根据器官不同在孔型γ计数器或在γ剂量校准器中计数。假设血量占体重的8%,以此为依据来计算剂量。下表1所示的共轭物的结果为两只大鼠的平均值,并以尾中残余剂量进行了修正。
与其它已知炎症造影剂如Ga-67、99mTc-IgG、111In-WBC和99mTc-Nanocoll相比,两种共轭物均给出了极好的闪烁扫描影象,通过测到的靶与背景间的高比率(发炎的:未发炎的肌肉)表明了这一点。该共轭物比已知试剂的造影速度快得多,且呈现优越的生物分布性。此外非靶器官如肝脏和胃肠道显示出很低的积累量。
造影剂 | 发炎的:未发炎的 | 体液:血 | 尿(剂量百分数) | 肝(剂量百分数) | 胃肠道(剂量百分数) |
N,N-二甲基Gly-Ser-Cys(Acm)-GTKPPR-OHN,N-二甲基Gly-Thr-Cys(Acm )-GTKPPR-OHN,N-二苄基Gly-Ser-Cys(Acm)-GTKPPR-OH | 5.34.63.7 | 1.91.60.4 | 63.568.555.1 | 2.42.42.3 | 2.82.57.5 |
67Ga99mTc-IgG111In-WBC99mTc-Nanocoll | 2.52.81.53.3 | 0.10.030.10.2 | 5.51.20.20.8 | 26.517.636.966.7 | 8.40.73.62.1 |
Claims (30)
其中
X是一直链或支链的、饱和或不饱和C1-4烷基链,该烷基链可任选地插入一个或两个选自N、O和S的杂原子;可任选地被至少一个选自卤素、羟基、氨基、羧基、C1-4烷基、芳基和C(O)Z的基团取代;
Y是H或X定义的取代基;
X和Y一起形成一个5-至8-元的饱和或不饱和杂环,该杂环可任选地被至少一个选自卤素、羟基、氨基、羧基、氧代、C1-4烷基、芳基和C(O)Z的基团取代;
R1至R4各自独立地选自H;羧基;C1-4烷基;被一个选自羟基、氨基、巯基、卤素、羧基、C1-4烷氧羰基和氨基羰基的基团取代的C1-4烷基;除脯氨酸外的D-或L-氨基酸的α碳侧链;和C(O)Z;
R5和R6各自独立地选自H;羧基;氨基;C1-4烷基;被羟基、羧基或氨基取代的C1-4烷基;和C(O)Z;
R7选自H和硫保护基;及
Z选自羟基、C1-4烷氧基和一个靶向性分子。
2.根据权利要求1的化合物,其中R1、R2、R4、R5和R6为氢。
3.根据权利要求1的化合物,其中X和Y各自独立地选自C1-4烷基和芳基取代的C1-4烷基。
4.根据权利要求1的化合物,其中R3选自羟甲基和1-羟乙基。
5.根据权利要求1的化合物,其中Y独立地为X定义的取代基。
6.根据权利要求5的化合物,其中X和Y为选自甲基、乙基和苄基的相同基团。
7.根据权利要求5的化合物,其中R3选自羟甲基和1-羟乙基。
8.根据权利要求5的化合物,其中R1、R2、R4、R5和R6为氢。
9.根据权利要求1的化合物,其中Z为靶向性分子。
10.根据权利要求9的化合物,其中靶向性分子是肽。
11.根据权利要求10的化合物,其中肽包含3个或多个氨基酸残基。
12.根据权利要求11的化合物,其中肽包含序列TKPPR。
13.根据权利要求12的化合物,其中肽包含序列Gly-Thr-Lys-Pro-Pro-Arg-OH。
14.根据前述任一权利要求的化合物,呈与金属放射性核素或其氧化物或氮化物配合的形式。
15.根据权利要求14的化合物,其中所述金属放射性核素选自99mTc、64Cu、67Cu、97Ru、105Rh、109Pd、186Re、188Re、198Au、199Au、203Pb、212Pb和212Bi。
16.根据权利要求14的化合物,其中所述金属放射性核素选自99mTc、186Re和188Re。
17.根据权利要求14的化合物,其中所述金属放射性核素为99mTc。
其中
X是一直链或支链、饱和或不饱和C1-4烷基链,该烷基链可任选地插入一个或两个选自N、O和S的杂原子;且可任选地被至少一个选自卤素、羟基、氨基、羧基、C1-4烷基、芳基和C(O)Z的基团取代;
Y是H或X定义的取代基;
X和Y可一起形成一个5-至8-元的饱和或不饱和杂环,该杂环可任选地被至少一个选自卤素、羟基、氨基、羧基、氧代、C1-4烷基、芳基和C(O)Z的基团取代;
R1至R4各自独立地选自H;羧基;C1-4烷基;被一个选自羟基、氨基、巯基、卤素、羧基、C1-4烷氧羰基和氨基羰基的基团取代的C1-4烷基;除脯氨酸外的D-或L-氨基酸的α碳侧链;和C(O)Z;
R5和R6各自独立地选自H;羧基;氨基;C1-4烷基;被羟基、羧基或氨基取代的C1-4烷基;和C(O)Z;
Z选自羟基、C1-4烷氧基和一个靶向性分子;和
M是一金属放射性核素或其氧化物或氮化物。
19.根据权利要求18的化合物,其中M选自99mTc、64Cu、67Cu、97Ru、105Rh、109Pd、186Re、188Re、198Au、199Au、203Pb、212Pb和212Bi及其氧化物或氮化物。
20.根据权利要求18的化合物,其中M选自99mTc、186Re和188Re及其氧化物或氮化物。
21.根据权利要求18的化合物,其中M是99mTc或其氧化物或氮化物。
22.一种探测靶向性分子在哺乳动物体内位置的方法,包括施用诊断有效量的权利要求14的化合物,其中Z是靶向性分子。
23.根据权利要求22的方法,其中所说的金属放射性核素为99mTc。
24.一种在哺乳动物体内对病灶炎症部位进行造影的方法,包括施用诊断有效量的权利要求10的化合物,该化合物呈与金属放射性核素或其氧化物或氮化物配合的形式。
25.根据权利要求24的方法,其中所述金属放射性核素是99mTc。
26.一种在哺乳动物体内对病灶炎症部位进行造影的方法,包括施用有效量的权利要求12的化合物,该化合物呈与金属放射性核素或其氧化物或氮化物配合的形式。
27.根据权利要求26的方法,其中所说金属放射性核素为99mTc。
28.根据权利要求1的化合物,它选自
N,N-二甲基Gly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg-OH;
N,N-二甲基Gly-Thr-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg-OH;
N,N-二乙基Gly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg-OH;和
N,N-二苄基Gly-Ser-Cys(Acm)-Gly-Thr-Lys-Pro-Pro-Arg-OH。
29.根据权利要求28的化合物,呈与金属放射性核素或其氧化物或氮化物配合的形式。
30.根据权利要求29的化合物,其中所述金属放射性核素为99mTc。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/279,155 US5662885A (en) | 1994-07-22 | 1994-07-22 | Peptide derived radionuclide chelators |
US08/279,155 | 1994-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1158133A true CN1158133A (zh) | 1997-08-27 |
Family
ID=23067872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95195127A Pending CN1158133A (zh) | 1994-07-22 | 1995-04-28 | 肽衍生的放射性核素螯合剂 |
Country Status (11)
Country | Link |
---|---|
US (3) | US5662885A (zh) |
EP (1) | EP0772628B1 (zh) |
JP (1) | JP3753734B2 (zh) |
CN (1) | CN1158133A (zh) |
AT (1) | ATE194845T1 (zh) |
AU (1) | AU700772B2 (zh) |
CA (1) | CA2194551A1 (zh) |
DE (1) | DE69518083T2 (zh) |
HU (1) | HUT77137A (zh) |
NO (1) | NO970273L (zh) |
WO (1) | WO1996003427A1 (zh) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238340B1 (en) | 1991-11-27 | 2007-07-03 | Cis Bio International | Monoamine, diamide, thiol-containing metal chelating agents |
US5645815A (en) * | 1991-02-08 | 1997-07-08 | Diatide, Inc. | Radiolabled compounds for thrombus imaging |
US5662885A (en) * | 1994-07-22 | 1997-09-02 | Resolution Pharmaceuticals Inc. | Peptide derived radionuclide chelators |
US5804158A (en) * | 1995-05-31 | 1998-09-08 | Resolution Pharmaceuticals Inc. | Sequestered imaging agents |
US6027711A (en) * | 1995-06-07 | 2000-02-22 | Rhomed Incorporated | Structurally determined metallo-constructs and applications |
US5688489A (en) * | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
FR2748747B1 (fr) * | 1996-05-20 | 1998-08-07 | Centre Nat Rech Scient | Particules virales recombinantes comportant un peptide ayant des proprietes de masquage et de demasquage vis-a-vis d'un mecanisme biologique |
CA2257856A1 (en) * | 1996-06-10 | 1997-12-18 | G.D. Searle & Co. | Radiopharmaceutical compositions capable of localizing at sites of thrombus |
DE69840647D1 (de) | 1997-04-22 | 2009-04-23 | Curator Of The University Of M | Konjugate aus peptiden, die liganden von gastrinrezeptoren sind |
US7060247B2 (en) | 1997-04-22 | 2006-06-13 | The Curators Of The University Of Missouri | Gastrin receptor-avid peptide conjugates |
US6017511A (en) * | 1997-05-30 | 2000-01-25 | Resolution Pharmaceuticals Inc. | Glycopeptide-chelator conjugates |
AU8849398A (en) * | 1997-08-21 | 1999-03-16 | Resolution Pharmaceuticals Inc. | Combinatorial library |
US6334996B1 (en) * | 1997-12-24 | 2002-01-01 | Resolution Pharmaceuticals Inc. | Chelators that predominantely form a single stereoisomeric species upon coordination to a metal center |
AU1865899A (en) * | 1997-12-24 | 1999-07-19 | Resolution Pharmaceuticals Inc. | Peptide chelators that predominately form a single stereoisomeric species upon coordination to a metal center |
WO1999051628A1 (en) | 1998-04-03 | 1999-10-14 | Du Pont Pharmaceuticals Company | Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer |
JP2002527358A (ja) | 1998-08-31 | 2002-08-27 | グリフォン サイエンシーズ | 脂質マトリックス介助化学連結方法および膜ポリペプチドの合成 |
JP2002536295A (ja) * | 1998-12-14 | 2002-10-29 | パラチン テクノロジーズ, インク. | 金属ペプチド組合せライブラリ及びその利用法 |
WO2000048639A1 (en) * | 1999-02-17 | 2000-08-24 | Resolution Pharmaceuticals Inc. | Immobilized labeling compounds and methods |
US6544279B1 (en) | 2000-08-09 | 2003-04-08 | Incept, Llc | Vascular device for emboli, thrombus and foreign body removal and methods of use |
US7482425B2 (en) | 1999-08-26 | 2009-01-27 | Amylin Pharmaceuticals, Inc. | Compositions for lipid matrix-assisted chemical ligation |
EP2279757A3 (en) | 2000-06-02 | 2011-08-03 | Bracco Suisse SA | Compounds for targeting endothelial cells |
US8263739B2 (en) * | 2000-06-02 | 2012-09-11 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
US7311893B2 (en) * | 2000-07-25 | 2007-12-25 | Neurochem (International) Limited | Amyloid targeting imaging agents and uses thereof |
US7422733B2 (en) * | 2000-11-29 | 2008-09-09 | Bracco International B.V. | Linkable sialyl Lewis X analogs |
US7893223B2 (en) | 2001-07-17 | 2011-02-22 | Bracco Imaging S.P.A. | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy |
EP2301587B1 (en) | 2002-03-01 | 2014-06-25 | Dyax Corp. | KDR and VEGF/KDR binding peptides and their use in diagnosis |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
WO2004065621A1 (en) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
US7850947B2 (en) | 2003-01-13 | 2010-12-14 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
US8420050B2 (en) | 2003-01-13 | 2013-04-16 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
US7611692B2 (en) | 2003-01-13 | 2009-11-03 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
US7226577B2 (en) | 2003-01-13 | 2007-06-05 | Bracco Imaging, S. P. A. | Gastrin releasing peptide compounds |
JP4610345B2 (ja) | 2003-01-13 | 2011-01-12 | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | 医薬品化合物のための改善されたリンカー |
US7922998B2 (en) | 2003-01-13 | 2011-04-12 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
DK2284180T3 (en) | 2003-03-03 | 2015-12-21 | Dyax Corp | Uses of peptides that specifically bind to the HGF receptor (cMET) |
RU2006105644A (ru) * | 2003-07-24 | 2006-08-10 | Бракко Имэджинг С.П.А. (It) | Стабильные радиофармацевтические композиции и способы их получения |
EP1737889B1 (en) | 2004-10-19 | 2010-09-08 | Lonza AG | Method for solid phase peptide synthesis |
EP1700608A1 (en) | 2005-03-10 | 2006-09-13 | Schering AG | Chelators for radioactively labeled conjugates comprising a stabilizing sidechain |
US9333272B2 (en) | 2006-12-11 | 2016-05-10 | Bracco Imaging Spa | Fibrin binding peptide conjugates for diagnostic and therapeutic applications |
WO2009105671A2 (en) * | 2008-02-21 | 2009-08-27 | Burnham Institute For Medical Research | Methods and compositions related to peptides and proteins with c-terminal elements cross-reference to related applications |
EP2147684A1 (en) | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
WO2010107832A1 (en) | 2009-03-17 | 2010-09-23 | Bracco Imaging Spa | Lhrh-ii peptide analogs |
JP5906184B2 (ja) | 2009-06-22 | 2016-04-20 | バーナム インスティテュート フォー メディカル リサーチ | C末端エレメントを有するペプチドおよびタンパク質を使用する方法および組成物 |
US20150344523A1 (en) | 2014-05-05 | 2015-12-03 | California Institute Of Technology | Mutant akt-specific capture agents, compositions, and methods of using and making |
WO2017011769A2 (en) | 2015-07-15 | 2017-01-19 | California Institute Of Technology | Il-17f-specific capture agents, compositions, and methods of using and making |
CN108699130A (zh) | 2016-02-09 | 2018-10-23 | 博莱科瑞士股份有限公司 | 用于选择素靶向的重组嵌合蛋白 |
CN115109120A (zh) | 2016-04-04 | 2022-09-27 | 英蒂分子公司 | Cd8-特异性捕获剂、组合物及使用和制备方法 |
WO2018064597A1 (en) | 2016-09-29 | 2018-04-05 | Indi Molecular, Inc. | Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same |
US11358982B2 (en) | 2016-11-01 | 2022-06-14 | Ohio State Innovation Foundation | Methods for the iodination of biomolecules |
EP3638687A1 (en) | 2017-06-15 | 2020-04-22 | Indi Molecular, Inc. | Il-17f and il-17a-specific capture agents, compositions, and methods of using and making |
US11638764B2 (en) | 2018-11-08 | 2023-05-02 | Indi Molecular, Inc. | Theranostic capture agents, compositions, and methods of using and making |
WO2020186091A1 (en) | 2019-03-12 | 2020-09-17 | Indi Molecular, Inc. | Cross-linked epitopes and methods of use thereof |
US20200371101A1 (en) | 2019-05-20 | 2020-11-26 | Indi Molecular, Inc. | Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1) |
US11414460B2 (en) | 2019-07-19 | 2022-08-16 | Institute For Systems Biology | KRAS-specific capture agents, compositions, and methods of making and using |
WO2022098743A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1) |
WO2022098745A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
EP4377296A1 (en) | 2021-07-26 | 2024-06-05 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4390528A (en) * | 1981-11-16 | 1983-06-28 | Research Corporation | Tuftsinyl-tuftsin |
US4980147A (en) * | 1984-06-25 | 1990-12-25 | University Of Utah Research Foundation | Radiolabeled technetium chelates for use in renal function determinations |
FR2575753B1 (fr) * | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US5187264A (en) * | 1986-05-28 | 1993-02-16 | Mallinckrodt Medical, Inc. | Technetium chelates to be used for determining the renal function |
ATE52516T1 (de) * | 1986-05-28 | 1990-05-15 | Mallinckrodt Inc | Technetiumchelate fuer die bestimmung der nierenfunktion. |
US5082930A (en) * | 1986-05-29 | 1992-01-21 | Mallinckrodt Medical, Inc. | Coupling agents for joining radionuclide metal ions with biologically useful proteins |
FR2610934B1 (fr) * | 1987-02-13 | 1989-05-05 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US4965392A (en) * | 1987-03-26 | 1990-10-23 | Neorx Corporation | Chelating compounds for metal-radionuclide labeled proteins |
US5091514A (en) * | 1987-03-26 | 1992-02-25 | Neorx Corporation | Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy |
FR2616663B1 (fr) * | 1987-06-16 | 1989-08-18 | Adir | Nouveaux tripeptides a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US5021567A (en) * | 1987-09-24 | 1991-06-04 | Abbott Laboratories | 8-hydroxyquinoline chelating agents |
US5202451A (en) * | 1988-02-17 | 1993-04-13 | Neorx Corporation | Anchimeric radiometal chelating compounds |
US5202109A (en) * | 1988-06-10 | 1993-04-13 | Neorx Corporation | Conjugates for bone imaging and bone cancer therapy |
IT1230712B (it) * | 1989-02-10 | 1991-10-29 | Sclavo Spa | Composizione per vaccini |
WO1990009172A1 (en) * | 1989-02-16 | 1990-08-23 | Pfizer Inc. | Phosphorus containing renin inhibitors |
US4986979A (en) * | 1989-03-14 | 1991-01-22 | Neorx Corporation | Imaging tissue sites of inflammation |
US5248764A (en) * | 1989-06-16 | 1993-09-28 | Merck Frosst Canada, Inc. | Chelate derivatives of atrial natriuretic factor (ANF) |
US5028593A (en) * | 1989-08-15 | 1991-07-02 | Board Of Regents, The University Of Texas System | Tuftsin analogs |
IT1232311B (it) * | 1989-09-04 | 1992-01-28 | Sclavo Spa | Metodo di purificazione di composti a struttura peptidica o pseudo peptidica a basso peso molecolare. |
US5175257A (en) * | 1989-12-29 | 1992-12-29 | Neorx Corporation | Radiolabeled proteins for diagnostic or therapeutic use |
EP0454302A3 (en) * | 1990-03-30 | 1992-10-14 | Banyu Pharmaceutical Co., Ltd. | Tuftsin derivatives |
US5112594A (en) * | 1991-04-04 | 1992-05-12 | Mallinckrodt Medical, Inc. | Kit for preparing a technetium-99m myocardial imaging agent |
ATE188387T1 (de) * | 1991-02-08 | 2000-01-15 | Diatide Inc | Technetium-99m markierte polypeptide zur bildformung |
WO1992019274A1 (en) * | 1991-05-08 | 1992-11-12 | Mallinckrodt Medical, Inc. | Technetium chelates to be used for determining the renal function |
DK0629133T3 (da) * | 1992-01-03 | 2001-04-02 | Rhomed Inc | Farmaceutisk anvendelse af peptidmetalioner |
GB9209641D0 (en) * | 1992-05-02 | 1992-06-17 | Johnson Matthey Plc | Improvements in radiolabelling |
DE69408145T2 (de) * | 1993-07-19 | 1998-09-03 | Resolution Pharm Inc | Hydrazine mit einer n3s konfiguration als radionukleide chelatoren |
JP4293632B2 (ja) * | 1993-11-16 | 2009-07-08 | ブラッコ インターナショナル ベースローテン フェンノートシャップ | 固定化標識方法 |
US5480970A (en) * | 1993-12-22 | 1996-01-02 | Resolution Pharmaceuticals | Metal chelators |
US5569745A (en) * | 1994-02-25 | 1996-10-29 | Resolution Pharmaceuticals Inc. | Peptide-Chelator conjugates |
US5662885A (en) * | 1994-07-22 | 1997-09-02 | Resolution Pharmaceuticals Inc. | Peptide derived radionuclide chelators |
US5804158A (en) * | 1995-05-31 | 1998-09-08 | Resolution Pharmaceuticals Inc. | Sequestered imaging agents |
-
1994
- 1994-07-22 US US08/279,155 patent/US5662885A/en not_active Expired - Lifetime
-
1995
- 1995-04-28 CA CA002194551A patent/CA2194551A1/en not_active Abandoned
- 1995-04-28 HU HU9700196A patent/HUT77137A/hu unknown
- 1995-04-28 WO PCT/CA1995/000249 patent/WO1996003427A1/en not_active Application Discontinuation
- 1995-04-28 DE DE69518083T patent/DE69518083T2/de not_active Expired - Lifetime
- 1995-04-28 AT AT95916539T patent/ATE194845T1/de not_active IP Right Cessation
- 1995-04-28 EP EP95916539A patent/EP0772628B1/en not_active Expired - Lifetime
- 1995-04-28 JP JP50532396A patent/JP3753734B2/ja not_active Expired - Fee Related
- 1995-04-28 AU AU23011/95A patent/AU700772B2/en not_active Ceased
- 1995-04-28 CN CN95195127A patent/CN1158133A/zh active Pending
- 1995-04-28 US US08/612,842 patent/US5976495A/en not_active Expired - Lifetime
-
1996
- 1996-08-28 US US08/703,988 patent/US5780006A/en not_active Expired - Lifetime
-
1997
- 1997-01-21 NO NO970273A patent/NO970273L/no unknown
Also Published As
Publication number | Publication date |
---|---|
DE69518083T2 (de) | 2001-03-22 |
DE69518083D1 (de) | 2000-08-24 |
NO970273D0 (no) | 1997-01-21 |
NO970273L (no) | 1997-03-12 |
ATE194845T1 (de) | 2000-08-15 |
US5976495A (en) | 1999-11-02 |
EP0772628A1 (en) | 1997-05-14 |
AU2301195A (en) | 1996-02-22 |
EP0772628B1 (en) | 2000-07-19 |
JPH10502931A (ja) | 1998-03-17 |
AU700772B2 (en) | 1999-01-14 |
JP3753734B2 (ja) | 2006-03-08 |
HUT77137A (hu) | 1998-03-02 |
US5780006A (en) | 1998-07-14 |
WO1996003427A1 (en) | 1996-02-08 |
CA2194551A1 (en) | 1996-02-08 |
US5662885A (en) | 1997-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1158133A (zh) | 肽衍生的放射性核素螯合剂 | |
JP2726320B2 (ja) | ペプチド誘導体 | |
AU683833B2 (en) | Protein- and peptide-metal ion pharmaceutical applications | |
US5443816A (en) | Peptide-metal ion pharmaceutical preparation and method | |
CN1093424C (zh) | 含单胺、联氨、硫羟基的金属螯合剂 | |
US5759515A (en) | Polyvalent peptide pharmaceutical applications | |
JP3918157B2 (ja) | ソマトスタチン結合性ペプチド−金属キレートコンジュゲート | |
US5700444A (en) | Chemotactic peptide pharmaceutical applications | |
JPH04500823A (ja) | ポリペプチド誘導体 | |
JP2000515514A (ja) | 放射性金属元素結合ペプチドの類似化合物 | |
CN1181096C (zh) | 环六肽抑生长素类似物 | |
CN1401661A (zh) | 血栓成像用的放射性标记化合物 | |
US5776894A (en) | Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors | |
JP2022133357A (ja) | がんイメージング及びがん放射線治療のための組成物及び方法 | |
US5753627A (en) | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis | |
SK2094A3 (en) | Somatostatine polypeptides, method of their preparing and using | |
US6123916A (en) | Therapeutic use of somatostatin peptides | |
JP7221937B2 (ja) | 腫瘍標的化ペプチドバリアント | |
US6551574B2 (en) | Tuftsin metallopeptide analogs and uses thereof | |
CN116284236B (zh) | 一种18f核素标记的生长抑素受体抑制剂探针及其制备方法和试剂盒 | |
CN1158621A (zh) | 用于血管疾病诊断的配位化合物 | |
AU2022257363A1 (en) | Folate receptor-targeted radiotherapeutic agents and their use | |
EP4146268A2 (en) | Methods of detecting and treating lung damage in respiratory-related viral infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |